NLRP3 inflammasome inhibitors and IL-1 inhibitors, such as anakinra (an IL-1R antagonist), rilonacept (IL-1 TRAP), and canakinumab (monoclonal anti-IL-1β antibody), have been tested in clinical trials and showed efficacy in the treatment of acute and chronic gout patients. The gene discussed is NLRP3; the disease is gout.